title: Effect of exogenous catecholamines on tumor necrosis factor alpha, interleukin-6, interleukin-10 and beta-endorphin levels following severe trauma.
abstract: Cytokines and endogenous opioids are mediators of the post traumatic inflammatory response. The aim of this study was to determine the effect of exogenous catecholamines on tumor necrosis factor alpha (TNFa), interleukin-6 (IL-6), interleukin-10 (IL-10) and beta(beta)-endorphin levels in patients with severe trauma, during the first 24 h after injury. Forty four traumatized patients with haemorrhage class III and IV were included in the study. Patients were divided in two groups: Group 1 (adrenergic, n=22) and Group 2 (non adrenergic, n=22), depending on the use of exogenous catecholamines. Blood samples were collected at 0, 2, 4 and 24 h time points. Baseline values were different between the two groups, but an altered pattern of release was observed for TNFa, IL-6, IL-10 and beta-endorphin levels in patients treated with catecholamines. ICU stay was longer for the adrenergic group, while survival after 1 month was significantly lower. Findings support an altered pattern of cytokine release during the early phase after trauma, probably due to catecholamine presence.
authors.affiliation: 2nd Department of Anaesthesiology, University of Athens, School of Medicine, Attikon Hospital, 1 Rimini Str, Chaidari 12462, Athens, Greece. chrysabatistaki@yahoo.gr
authors.forename: Chrysanthi
authors.initials: C
authors.lastname: Batistaki
authors.forename: Georgia
authors.initials: G
authors.lastname: Kostopanagiotou
authors.forename: Pavlos
authors.initials: P
authors.lastname: Myrianthefs
authors.forename: Cleanthi
authors.initials: C
authors.lastname: Dimas
authors.forename: Paraskevi
authors.initials: P
authors.lastname: Matsota
authors.forename: Aggeliki
authors.initials: A
authors.lastname: Pandazi
authors.forename: George
authors.initials: G
authors.lastname: Baltopoulos
mesh_terms: D000328:Adult; D000368:Aged; D002395:Catecholamines / Q000008:administration & dosage*; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007262:Infusions, Intravenous; D007362:Intensive Care Units; D016753:Interleukin-10 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D012771:Shock, Hemorrhagic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*; D014947:Wounds and Injuries / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D001615:beta-Endorphin / Q000097:blood*
chemical_list: D002395:Catecholamines; C508609:IL10 protein, human; C508600:IL6 protein, human; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D001615:beta-Endorphin